Protocol Ledger

NCT03753763 · Phase II · COMPLETED

Safinamide for Multiple System Atrophy (MSA)

Interventional Phase II clinical trial protocol NCT03753763 sponsored by Zambon SpA in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-29 Enrollment: 49 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03753763
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)49 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03753763
Protocol FieldVerified Registry Value
NCT IdentifierNCT03753763
Consolidated Lead SponsorZambon SpA
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment49 participants (ACTUAL)
Registered Start Date2019-10-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03753763
Hospital Research SiteLocationSite Profile
Azienda Ospedaliera Di PadovaPadova, ItalyOpen Hospital Dossier ->
Istituto Clinico HumanitasRozzano, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI